Policy & Regulation
Alcon completes acquisition of Aerie Pharmaceuticals
22 November 2022 -

Eye care solutions company Alcon (SIX: ALC) (NYSE: ALC) confirmed on Tuesday that it has completed its acquisition of ophthalmic pharmaceutical specialist Aerie Pharmaceuticals Inc (NASDAQ: AERI).

The total purchase consideration was approximately USD930m.

Through this transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.

Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie's existing research and development capabilities, the company said.

Alcon intends to fully integrate Aerie into its business.



Related Headlines